During perimenopause and menopause, fluctuations in estrogen and progesterone can make the body’s stress response more ...

Small snacks, random tastings, and everyday habits quietly add hundreds of calories. This is how a small surplus accumulates ...

Wegovy is a Food and Drug Administration-approved weight loss medication for people with obesity or those who are overweight with weight-related health conditions. In recent years, interest in GLP-1 ...

Can late-night eating make you gain weight? The short answer: It’s complicated. While the occasional late-night snack won’t necessarily add inches to your waistline, consistently eating later in the ...

Semaglutide is the active ingredient in Ozempic®, which is approved by the Food and Drug Administration (FDA) to help people with type 2 diabetes manage their blood sugar levels. Healthcare providers ...

A massive review of 23 randomized trials found that statins do not cause the vast majority of side effects listed on their labels. Memory problems, depression, sleep issues, weight gain, and many ...

Note: The U.S. Food and Drug Administration (FDA) does not approve supplements for safety or effectiveness before being sold or marketed. Talk to a healthcare professional about whether a supplement ...

Self-love is far from a piece of cake, but Valerie Bertinelli has come a long way in her body positivity journey. Bertinelli, 65, got candid on her changing views on weight loss, including her alleged ...

Too good to be true? While blockbuster GLP-1 drugs continue to reach new heights in popularity, they’re not without potential downsides, like bizarre side effects such as “Ozempic feet.” And while ...

Oprah Winfrey shared an update on her weight loss medication experience. She said the injections, for her, will be “a lifetime thing.” She also opened up about how she’s feeling now and her mild side ...

GLP-1 medications have dominated the weight-loss landscape this year — but some older Americans are reportedly kicking the trend to the curb. A study published in JAMA in January 2025 — which looked ...